Paul M. Ridker

8 ta ish

Harvard University

1. Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

   Paul M. Ridker, Brendan M. Everett, Tom Thurén +25

   MaqolaOAOchiq kirish20177 iqtibos

   ABIABI:AkademIndex/2026.other.057723

2. From C-Reactive Protein to Interleukin-6 to Interleukin-1

   Paul M. Ridker

   Sharh maqolaOAOchiq kirish20165 iqtibos

   ABIABI:AkademIndex/2026.other.057700

3. A guiding map for inflammation

   Mihai G. Netea, Frances R. Balkwill, Michel Chonchol +29

   Maqola20174 iqtibos

   ABIABI:AkademIndex/2026.other.591507

4. Inflammation and Atherosclerosis

   Peter Libby, Paul M. Ridker, Attilio Maseri

   Sharh maqola20023 iqtibos

   ABIABI:AkademIndex/2026.other.197111

5. Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk

   Stephen J. Nicholls, A. Michael Lincoff, Michelle Garcia +19

   MaqolaOAOchiq kirish20202 iqtibos

   ABIABI:AkademIndex/2026.other.057794

6. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

   Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca +11

   Maqola20092 iqtibos

   ABIABI:AkademIndex/2026.other.072357

7. IL-6 inhibition with ziltivekimab in patients at high atherosclerotic risk (RESCUE): a double-blind, randomised, placebo-controlled, phase 2 trial

   Paul M. Ridker, Matt Devalaraja, Florian M.M. Baeres +9

   MaqolaOAOchiq kirish20212 iqtibos

   ABIABI:AkademIndex/2026.other.216651

8. The Long- and Short-Term Impact of Elevated Body Mass Index on the Risk of New Atrial Fibrillation

   Usha B. Tedrow, David Conen, Paul M. Ridker +5

   Maqola20102 iqtibos

   ABIABI:AkademIndex/2026.other.295653